TAK-700 R-form Catalog No.:M22571-C 5 µM) and dose-dependently increases

5 µM) and dose-dependently increases osteocalcin mRNA expression (0

(t1/2) supports the non-surmountability profile of SB-649868 (t1/2=35

Solubility: DMSO : 250 mg/mL (1145

O=C1C2=CC=CC3CCC[C@@H](CN1[C@H]1CN4CCC1CC4)C=32

1992 May-Jun

TAK-700 R-form Catalog No.:M22571-C 5 µM) and dose-dependently increasesTAK 700 R form is a highly selective inhibitor of 17, 20 lyase with IC50 value of 38nM . TAK 700 is a potent and selective inhibitor of the 17, 20 lyase activity of CYP17A1 which is responsible for androgen biosynthesis. Thus, TAK 700 is selected as a candidate for treatment of prostate cancer through reducing the adrenal androgen production. As an inhibitor of CYP17A1, the selectivity of TAK 700 is important to avoid causing the drugdrug interactions